Palmitoyl Tripeptide-1 (Pal-GHK)

Palmitoyl Tripeptide-1 is a lipopeptide fragment of collagen that stimulates collagen I, III, and fibronectin synthesis through TGF-β pathway activation. It is a key component of the Matrixyl 3000 complex.

Palmitoyl Tripeptide-1 is a palmitoylated derivative of the GHK (glycyl-L-histidyl-L-lysine) peptide fragment, classified as a signal peptide in cosmetic science. By mimicking collagen breakdown products, it signals fibroblasts to synthesize new extracellular matrix components.

Overview

Palmitoyl Tripeptide-1 belongs to the class of matrikine peptides -- small peptide fragments released during extracellular matrix turnover that regulate cell activities including proliferation, migration, and matrix synthesis. The palmitoyl (C16 fatty acid) moiety is attached to enhance lipophilicity and improve penetration through the stratum corneum.

The peptide is a core component of Matrixyl 3000, a proprietary complex developed by Sederma that combines Pal-Tripeptide-1 with Palmitoyl Tetrapeptide-7. While Pal-Tripeptide-1 drives collagen neosynthesis, the tetrapeptide-7 component reduces inflammatory cytokine production (particularly IL-6), providing a dual mechanism that addresses both matrix degradation and chronic low-grade inflammation associated with skin aging.

Mechanism of Action

Palmitoyl Tripeptide-1 functions as a signal peptide that mimics the small peptide fragments generated during collagen degradation. When collagen is broken down by matrix metalloproteinases (MMPs), the resulting fragments act as positive-feedback signals to fibroblasts, prompting new collagen synthesis. Pal-Tripeptide-1 replicates this signaling cascade.

The primary pathway involves activation of TGF-β (transforming growth factor beta) signaling. Upon binding to fibroblast receptors, the peptide upregulates TGF-β production, which in turn activates Smad-dependent transcription of procollagen genes. This leads to increased synthesis of:

  • Collagen type I -- the predominant structural collagen in dermis
  • Collagen type III -- important for skin elasticity and wound repair
  • Fibronectin -- a glycoprotein critical for cell adhesion and ECM organization

The palmitoyl chain facilitates membrane interaction and cellular uptake, improving bioavailability at the dermal-epidermal junction compared to unmodified GHK.

Additionally, Pal-Tripeptide-1 has been shown to upregulate hyaluronic acid synthase expression, contributing to improved dermal hydration and plumping effects that complement its structural collagen benefits. The peptide also modulates MMP expression, reducing enzymatic degradation of existing collagen while simultaneously promoting new synthesis -- a dual mechanism that accelerates net collagen accumulation.

Reconstitution Calculator

Reconstitution Calculator

Calculate your peptide dosing

Draw Volume
0.100mL
Syringe Units
10units
Concentration
2,500mcg/mL
Doses / Vial
20doses
Vial Total
5mg
Waste / Vial
0mcg
Syringe Cap.
100units · 1mL
How to reconstitute
Gather & prepare
1/6Gather & prepare

Set up a clean workspace with all supplies ready.

1.Wash hands thoroughly, put on disposable gloves
2.Your 5mg peptide vial (lyophilized powder)
3.Bacteriostatic water (you'll need 2mL)
4.A 3–5mL syringe with 21–25 gauge needle for reconstitution
5.Alcohol swabs (70% isopropyl)
Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Sterile water is only safe for single-use.
Supply Planner

7x / week for weeks

·
40%
2vials
28 doses20 days/vial12 leftover
Cost Breakdown
Vial price
$0.00per dose
$0.00 /week$0 /month
Store 2-8°C30 day shelf lifeSwirl gentlyFor research purposes only

Research

Collagen Stimulation

In vitro studies using human dermal fibroblast cultures demonstrate that Palmitoyl Tripeptide-1 stimulates collagen synthesis in a dose-dependent manner. Lintner et al. (2009) reported significant upregulation of procollagen I and III production, with concomitant increases in fibronectin and glycosaminoglycan synthesis. The effect was comparable to or greater than that of retinol at equivalent concentrations in certain assay conditions.

Matrixyl 3000 Clinical Data

Clinical evaluation of Matrixyl 3000 (Pal-Tripeptide-1 + Pal-Tetrapeptide-7) applied at 3% concentration twice daily for 56 days demonstrated measurable improvements in wrinkle depth, skin firmness, and overall skin texture. Robinson et al. (2005) documented wrinkle volume reduction and improvements in skin roughness parameters using profilometric analysis.

Comparison with Parent Peptide GHK

The native GHK tripeptide has well-documented wound-healing and collagen-stimulating properties. Pickart et al. (2015) characterized GHK as a broad-spectrum regenerative signal capable of modulating over 4,000 genes. Palmitoylation enhances skin penetration without significantly altering the binding affinity for target receptors. Studies comparing Pal-GHK to unmodified GHK show improved dermal delivery and sustained activity when formulated in emulsion systems.

Formulation Considerations

Palmitoyl Tripeptide-1 is typically supplied as a pre-dissolved concentrate for incorporation into cosmetic formulations. The palmitoyl chain provides good compatibility with oil-in-water emulsion systems, which are the preferred vehicle type. The peptide is stable at pH 5.0-6.5 and should be added to formulations below 40C to prevent thermal degradation. When formulated as part of Matrixyl 3000, the two peptide components are pre-blended at optimized ratios by Sederma.

Recommended use levels are typically 2-4% of the commercial solution in finished products. The peptide is compatible with most cosmetic preservative systems and can be combined with other anti-aging actives including retinoids, vitamin C derivatives, and hyaluronic acid without stability concerns.

Safety Profile

Palmitoyl Tripeptide-1 has an excellent safety profile in topical applications. No significant adverse reactions have been reported in clinical studies at concentrations up to 5%. Dermal irritation and sensitization testing demonstrate minimal potential for allergic contact dermatitis. The peptide does not exhibit phototoxicity or mutagenicity in standard safety assays. As a naturally occurring peptide fragment with a lipid modification, it is generally regarded as safe for cosmetic use by regulatory authorities including the EU Scientific Committee on Consumer Safety. Long-term use studies spanning 12 months of daily application have confirmed sustained safety with no cumulative adverse effects.

Pharmacokinetic Profile

Quick Start

Route
Topical (serum, cream)

Research Protocols

topical

Safety Profile Palmitoyl Tripeptide-1 has an excellent safety profile in topical applications.

GoalDoseFrequency
General Research ProtocolSee literatureTwice daily

Interactions

Peptide Interactions

Parent Peptide GHKmonitor

The native GHK tripeptide has well-documented wound-healing and collagen-stimulating properties. Pickart et al. (2015) characterized GHK as a broad-spectrum regenerative signal capable of modulating over 4,000 genes. Palmitoylation enhances skin penetration without significantly altering the bind...

What to Expect

What to Expect

Week 6-8

Clinical evaluation of Matrixyl 3000 (Pal-Tripeptide-1 + Pal-Tetrapeptide-7) applied at 3% concentration twice daily for 56 days demonstrated...

Month 9-12

Long-term use studies spanning 12 months of daily application have confirmed sustained safety with no cumulative adverse effects.

Ongoing

Continued use as directed

Quality Indicators

What to look for

  • Naturally occurring compound

Frequently Asked Questions

References (4)

  1. [5]
  2. [1]
  3. [4]
  4. [2]
    Lintner K et al Cosmetic peptides Int J Cosmet Sci (2009)
Updated 2026-03-08Reviewed by Tides Research Team4 citationsSources: peptide-wiki-mdx, peptide-wiki-mdx-v2

On this page